|
1
|
Darnell JE: Transcription factors as
targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Darnell JE: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bromberg J and Darnell JE: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ihle JN: STATs: signal transducers and
activators of transcription. Cell. 84:331–334. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herrington J, Smit LS, Schwartz J and
Carter-Su C: The role of STAT proteins in growth hormone signaling.
Oncogene. 19:2585–2597. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alvarez JV, Greulich H, Sellers WR,
Meyerson M and Frank DA: Signal transducer and activator of
transcription 3 is required for the oncogenic effects of
non-small-cell lung cancer-associated mutations of the epidermal
growth factor receptor. Cancer Res. 66:3162–3168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yin W, Cheepala S, Roberts JN, Syson-Chan
K, DiGiovanni J and Clifford JL: Active Stat3 is required for
survival of human squamous cell carcimoma cells in serum-free
conditions. Mol Cancer. 5:152006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kusaba T, Nakayama T, Yamazumi K, et al:
Activation of STAT3 is a marker of poor prognosis in human
colorectal cancer. Oncol Rep. 15:1445–1451. 2006.PubMed/NCBI
|
|
9
|
Morikawa T, Baba Y, Yamauchi M, et al:
STAT3 expression, molecular features, inflammation patterns, and
prognosis in a database of 724 colorectal cancers. Clin Cancer Res.
17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de la Iglesia N, Konopka G, Lim KL, et al:
Deregulation of a STAT3-interleukin 8 signaling pathway promotes
human glioblastoma cell proliferation and invasiveness. J Neurosci.
28:5870–5878. 2008.PubMed/NCBI
|
|
11
|
de la Iglesia N, Konopka G, Puram SV, et
al: Identification of a PTEN-regulated STAT3 brain tumor suppressor
pathway. Genes Dev. 22:449–462. 2008.PubMed/NCBI
|
|
12
|
Copeland NG, Gilbert DJ, Schindler C, et
al: Distribution of the mammalian Stat gene family in mouse
chromosomes. Genomics. 29:225–228. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lai SY and Johnson FM: Defining the role
of the JAK-STAT pathway in head and neck and thoracic malignancies:
implications for future therapeutic approaches. Drug Resist Updat.
13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Quesnelle KM, Boehm AL and Grandis JR:
STAT-mediated EGFR signaling in cancer. J Cell Biochem.
102:311–319. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao L, Zhang L, Hu J, et al:
Down-regulation of signal transducer and activator of transcription
3 expression using vector-based small interfering RNAs suppresses
growth of human prostate tumor in vivo. Clin Cancer Res.
11:6333–6341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kisseleva T, Bhattacharya S, Braunstein J
and Schindler CW: Sigaling through the JAK-STAT pathway, recent
advances and future challenges. Gene. 285:1–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, et al: Signal tansducer and activator of transcription-3,
inflammation, and cancer. Ann NY Acad Sci. 1171:59–76. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pawson T, Gish GD and Nash P: SH2 domains,
interaction modules and cellular wiring. Trends Cell Biol.
11:504–511. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhong Z, Wen Z and Darnell JE: Stat3, a
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leeman R, Lui VWY and Grandis JR: STAT3 as
a therapeutic target in head and neck cancer. Expert Opin Biol
Ther. 6:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takeda K, Noguchi K, Shi W, et al:
Targeted disruption of the mouse Stat3 gene leads to early
embryonic lethality. Proc Natl Acad Sci USA. 94:3801–3804. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang XO, Panopoulos AD, Nurieva R, et al:
STAT3 regulates cytokine-mediated generation of inflammatory helper
T cells. J Biol Chem. 282:9358–9363. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyoshi K, Takaishi M, Nakajima K, et al:
Stat3 as a therapeutic target for the treatment of psoriasis: a
clinical feasibility study with STA-21, a Stat3 inhibitor. J Invest
Dermatol. 131:108–117. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang HY, Zhang Q, Zhang X, et al:
Cancer-related inflammation and Barrett’s carcinogenesis:
interleukin-6 and STAT3 mediate apoptotic resistance in transformed
Barrett’s cells. Am J Physiol Gastrointest Liver Physiol.
300:G454–G460. 2011.
|
|
25
|
Mora LB, Buettner R, Seigne J, et al:
Constitutive activation of Atat3 in human prostate tumors and cell
lines: direct inhibition of Stat3 signaling induces apoptosis of
prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
26
|
Burger R, Le Gouill S, Tai Y-T, et al:
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic
effects on human myeloma cells in vitro and in vivo. Mol Cancer
Ther. 8:26–35. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei L-H, Kuo M-L, Chen C-A, et al:
Interleukin-6 promotes cervical tumor growth by VEGF-dependent
angiogenesis via a STAT3 pathway. Oncogene. 22:1517–1527. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lopiccolo J, Blumenthal G, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sasse J, Hemmann U, Schwartz C, et al:
Mutational analysis of acute-phase response factor/Stat3 activation
and dimerization. Mol Cell Biol. 17:4677–4686. 1997.PubMed/NCBI
|
|
30
|
Shuai K, Horvath CM, Huang LHT, Qureshi S,
Cowburn D and Darnell JE: Interferon activation of the
transcription factor Stat91 involves dimerization through
SH2-phosphotyrosyl peptide interactions. Cell. 76:821–828. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fletcher S and Gunning PT: Mild, efficient
and rapid O-debenzylation of ortho-substituted phenols with
trifluoroacetic acid. Tetrahedron Lett. 49:4817–4819. 2008.
View Article : Google Scholar
|
|
32
|
Yu C-L, Meyer DJ, Campbell GS, et al:
Enhanced DNA-binding activity of a Stat3-related protein in cells
transformed by the Src oncoprotein. Science. 269:81–83. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Smithgall TE, Briggs SD, Schreiner S,
Lerner EC, Cheng H and Wilson MB: Control of myeloid
differentiation and survial by Stats. Oncogene. 19:2612–2618. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bowman T, Garcia R, Turkson J and Jove R:
STATs in oncogenesis. Oncogene. 19:2474–2488. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Catlett-Falcone R, Dalton WS and Jove R:
STAT proteins as novel targets for cancer therapy. Curr Opin Oncol.
11:490–496. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Inamura K, Matsuzaki Y, Uematsu N, Hondab
A, Tanaka N and Uchida K: Rapid inhibition of MAPK signaling and
anti-proliferation effect via JAK/STAT signaling by
interferon-alpha in hepatocellular carcinoma cell lines. Biochim
Biophys Acta. 1745:401–410. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yang JL, Zahorowska B, Kasim Y, Goldstein
D and Crowe P: Mechanism of the synergistic antiproliferative
effect of gefitinib and interferon-alpha in sarcoma cell lines.
Proc 101st Ann Meet AACR. 398–399:(abs. 1655). 2010.
|
|
38
|
Turkson J and Jove R: STAT proteins: novel
molecular targets for cancer drug discovery. Oncogene.
19:6613–6626. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Aggarwal BB, Sethi G, Ahn KS, et al:
Targeting signal-transducer-and-activator-of-transcription-3 for
prevention and therapy of cancer. Ann NY Acad Sci. 1091:151–169.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jaganathan S, Yue P, Paladino DC,
Bogdanovic J, Huo Q and Turkson J: A functional nuclear epidermal
growth factor receptor, Src and Stat3 heteromeric complex in
pancreatic cancer cells. PLoS One. 6:e196052011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Arany I, Chen S-H, Megyesi JK, et al:
Differentiation-dependent expression of signal transducers and
activators of transcription (STATs) might modify responses to
growth factors in the cancers of the head and neck. Cancer Lett.
199:83–89. 2003. View Article : Google Scholar
|
|
43
|
Masuda M, Suzui M, Yasumatu R, et al:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
44
|
Chun K-S and Langenbach R: The
prostaglandin E2 receptor, EP2, regulates survivin expression via
an EGFR/STAT3 pathway in UVB-exposed mouse skin. Mol Carcinog.
50:439–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Grandis JR, Drenning SD, Zeng Q, et al:
Contitutive activation of Stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA.
97:4227–4232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kijima T, Niwa H, Steinman RA, et al:
STAT3 activation abrogates growth factor dependence and contributes
to head and neck squamous cell carcinoma tumor growth in vivo. Cell
Growth Differ. 13:355–362. 2002.PubMed/NCBI
|
|
47
|
Huang M, Page C, Reynolds K and Lin J:
Constitutive activation of Stat 3 oncogene product in human ovarian
carcinoma cells. Gynecol Oncol. 79:67–73. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Niu G, Bowman T, HUang M, et al: Roles of
activated Src and Stat3 signaling in melanoma tumor cell growth.
Oncogene. 21:7001–7010. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen CL, Hsieh FC, Lieblein JC, et al:
Stat3 activation in human endometrial and cervical cancers. Br J
Cancer. 96:591–599. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Van der Fits L, van Kester MS, Qin Y, et
al: MicroRNA-21 expression in CD4+ T cells is regulated
by STAT3 and is pathologically involved in Sézary Syndrome. J
Invest Dermatol. 131:762–768. 2010.PubMed/NCBI
|
|
51
|
Loffler D, Brocke-Heidrich K, Pfeifer G,
et al: Interleukin-6 dependent survival of multiple myeloma cells
involves the Stat3-mediated induction of microRNA-21 through a
highly conserved enhancer. Blood. 110:1330–1333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ahluwalia A, Busse BA, Thiruvengadam SS
and Tarnawski AS: Importins are critical for colorectal cancer
(CRC) growth a nd are novel biomarkers of CRC. Underlying
mechanisms include: increased nuclear transport of P-CREB and
p-STAT3, VEGF gene promoter activation and aberrant VEGF
expression. Gastroenterology. 140:S1842011.
|
|
53
|
Wei D, Le X, Zheng L, et al: Stat3
activation regulates the expression of vascular endothelial growth
factor and human pancreatic cancer angiogenesis and metastasis.
Oncogene. 22:319–329. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xu Q, Briggs J, Park S, et al: Targeting
Stat3 blocks both HIF-1 and VEGF expression induced by multiple
oncogenic growth signaling pathways. Oncogene. 24:5552–5560. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xie T-X, Wei D, Liu M, et al: Stat3
activation regulates the expression of matrix metalloproteinase-2
and tumor invasion and metastasis. Oncogene. 23:3550–3560. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Dechow TN, Pedranzini L, Leitch A, et al:
Requirement of matrix metalloproteinase-9 for the transformation of
human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci USA.
101:10602–10607. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yu H, Kortylewski M and Pardoll D:
Crosstalk between cancer and immune cells: role of STAT3 in the
tumour microenvironment. Immunology. 7:41–51. 2007.PubMed/NCBI
|
|
58
|
Kortylewski M, Kujawski M, Wang T, et al:
Inhibiting Stat3 signaling in the hematopoietic system elicits
multicomponent antitumor immunity. Nat Med. 11:1314–1321. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kortylewski M and Yu H: Role of Stat3 in
suppressing anti-tumor immunity. Curr Opin Immunol. 20:228–233.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang T, Niu G, Kortylewski M, et al:
Regulation of the innate and adaptive immune responses by Stat-3
signaling in tumor cells. Nat Med. 10:48–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Garcia R, Bowman TL, Niu G, et al:
Constitutive activation of STAT3 by the Src and JAK tyrosine
kinases participates in growth regulation of human breast carcinoma
cells. Oncogene. 20:2499–2513. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Nagpal JK, Mishra R and Das BR: Activation
of Stat-3 as one of the early events in tobacco chewing-mediated
oral carcinogenesis. Cancer. 94:2393–2400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Deng J-Y, Sun D, Liu X-Y, Pan Y and Liang
H: STAT-3 correlates with lymph node metastasis and cell survival
in gastric cancer. World J Gastroenterol. 16:5380–5387. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Watson CJ and Miller WR: Elevated levels
of members of the STAT family of transcription factors in breast
carcinoma nuclear extracts. Br J Cancer. 71:840–844. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kosaka T, Yamaki E, Mogi A and Kuwano H:
Mechanisms of resistance to EGFR TKIs and development of a new
generation of drugs in non-small-cell lung cancer. J Biomed
Biotechnol. 2011:1–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Himpe E and Kooijman R: Insulin-like
growth factor-I receptor signal transduction and the Janus
kinase/signal transducer and activator of transcription (JAK-STAT)
pathway. Biofactors. 35:76–81. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sporeno E, Savino R, Ciapponi L, et al:
Human interleukin-6 receptor super-antagonists with high potency
and wide spectrum on multiple myeloma cells. Blood. 87:4510–4519.
1996.PubMed/NCBI
|
|
68
|
Demartis A, Bernassola F, Savino R, Melino
G and Ciliberto G: Interleukin 6 receptor superantagonists are
potent inducers of human multiple. Cancer Res. 56:4213–4218.
1996.PubMed/NCBI
|
|
69
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, et al: Constitutive activation of Stat3 signaling confers
resistance to apoptosis in human U266 myeloma cells. Immunity.
10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Johnson FM, Saigal B, Talpaz M and Donato
NJ: Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses
invasion and induces cell cycle arrest and apoptosis of head and
neck squamous cell carcinoma and non-small cell lung cancer cells.
Clin Cancer Res. 11:6924–6932. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Perry E, Tsruya R, Levitsky P, et al:
TMF/ARA160 is a BC-box-containing protein that mediates the
degradation of Stat3. Oncogene. 23:8908–8919. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Gu Q, Kong Y, Yu Z-B, Bai L and Xiao Y-B:
Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB
activation in congenital heart disease. Biochimie. 93:909–920.
2011.PubMed/NCBI
|
|
73
|
Ulane CM, Kentsis A, Cruz CD, Parisien
J-P, Schneider KL and Horvath CM: Composition and assembly of
STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein
carboxyl terminus is an oligomerization domain. J Virol.
79:10180–10189. 2005. View Article : Google Scholar
|
|
74
|
Lesina M, Kurkowski Magdalena U, Ludes K,
et al: Stat3/Socs3 activation by IL-6 transsignaling promotes
progression of pancreatic intraepithelial neoplasia and development
of pancreatic Cancer. Cancer Cell. 19:456–469. 2011. View Article : Google Scholar
|
|
75
|
Lindemann C, Hackmann O, Delic S, Schmidt
N, Reifenberger G and Riemenschneider MJ: SOCS3 promoter
methylation methylation is mutually exclusive to EGFR amplification
in gliomas and promotes glioma cell invasion through STAT3 and FAK
activation. Acta Neuropathol. 122:241–251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kluge A, Dabir S, Vlassenbroeck I,
Eisenberg R and Dowlati A: Protein inhibitor of activated STAT3
expression in lung cancer. Mol Oncol. 5:256–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Migone T-S, Cacalano NA, Taylor N, Yi T,
Waldmann TA and Johnston JA: Recruitment of SH2-containing protein
tyrosine phosphatase SHP-1 to the interleukin 2 recepto; loss of
SHP-1 expression in human T-lymphotropic virus type I-transformed T
cells. Proc Natl Acad Sci USA. 95:3845–3850. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Schaper F, Gendo C, ECK M, et al:
Activation of the protein tyrosine phosphatease SHP2 via the
interleukin-6 signal transducing receptor protein gp130 requires
tyrosine Jak1 and limits acute-phase protein expression. Biochem J.
355:557–565. 1998.
|
|
79
|
Irie-Sasaki J, Sasaki T, Matsumoto W, et
al: CD45 is a JAK phosphatase and negatively regulates cytokine
recptor signalling. Nature. 409:349–354. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Sun S and Steinberg BM: PTEN is a negative
regualtor of STAT3 activation in human papillomavirus-infected
cells. J Gen Virol. 83:1651–1658. 2002.PubMed/NCBI
|
|
81
|
Desrivières S, Kunz C, Barash I,
Vafaizadeh V, Borghouts C and Groner B: The biological functions of
the versatile transcription factors STAT3 and STAT5 and new
strategies for their targeted inhibition. J Mammary Gland Biol
Neoplasia. 11:75–87. 2006.PubMed/NCBI
|
|
82
|
Scoles DR, Nguyen VD, Qin Y, et al:
Neurofibromatosis 2 (NF2) tumor suppressor schwannomin and its
interacting protein HRS regulate STAT singling. Hum Mol Genet.
11:3179–3189. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bhasin D, Cisek K, Pandharkar T, et al:
Design, synthesis, and studies of small molecule STAT3 inhibitors.
Bioorg Med Chem Lett. 18:391–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
|
85
|
Akao Y, Nakagawa Y and Naoe T: let-7
MicroRNA functions as a potential grwoth suppressor in human colon
cancer cells. Biol Pharm Bull. 29:903–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Takamizawa J, Konishi H, Yanagisawa K, et
al: Reduced expression of the let-7 microRNAs in human lung cancers
in association with shortened postoperative survival. Cancer Res.
64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yanaihara N, Caplen N, Bowman E, et al:
Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Johnson SM, Grosshans H, Shingara J, et
al: RAS is regulated by the let-7 microRNA family. Cell.
120:635–647. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
He L, Thomson JM, Hemann MT, et al: A
microRNA polycistron as a potential human oncogene. Nature.
435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Foshay KM and Gallicano GI: miR-17 family
miRNAs are expressed during early mammalian development and
regulate stem cell differentiation. Dev Biol. 326:431–443. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Krichevsky AM, Sonntag K-C, Isacson O and
Kosik KS: Specific microRNAs modulate embryonic stem cell-derived
neurogenesis. Stem Cells. 24:857–864. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Meng F, Henson R, Wehbe-Janek H, Smith H,
Ueno Y and Patel T: The microRNA let-7a modulates
interleukin-6-dependent STAT-3 survival signaling in malignant
human cholangiocytes. J Biol Chem. 282:8256–8264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Niu G, Heller R, Catlett-Falcone R, et al:
Gene therapy with dominant-negative Stat3 suprresses growth of the
murine melanoma B16 tumor in vivo. Cancer Res. 59:5059–5063.
1999.PubMed/NCBI
|
|
95
|
Niu G, Shain KH, Huang M, et al:
Overexpression of a dominant-negative signal transducer and
activator of trnascription 3 varian in tumor cells leads to
production of soluble factors that induce apoptosis and cell cycle
arrest. Cancer Res. 61:3276–3280. 2001.PubMed/NCBI
|
|
96
|
Mishra PJ and Merlino G: MicroRNA
reexpression as differentiation therapy in cancer. J Clin Invest.
119:2119–2123. 2009.PubMed/NCBI
|
|
97
|
Liang Z-W, Guo B-F, Li Y, et al:
Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles
suppresses mouse prostate tumour growth in vivo. Asian J Androl.
13:481–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Petrocca F and Lieberman J: Promise and
chanllenge of RNA interference-based therapy for cancer. J Clin
Oncol. 29:747–754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Fletcher S, Drewry JA, Shahani VM, Page
BDG and Gunning PT: Molecular disruption of oncogenic signal
transducer and activator of transcription 3 (STAT3) protein.
Biochem Cell Biol. 87:825–833. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Turkson J, Ryan D, Kim JS, et al:
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity,
gene regulation, and cell transformation. J Biol Chem.
276:45443–45455. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Turkson J, Kim JS, Zhang S, et al: Novel
peptidomimetic inhibitors of signal transducer and activator of
transcription 3 dimerization and biological activity. Mol Cancer
Ther. 3:261–269. 2004.PubMed/NCBI
|
|
102
|
Siddiquee K, Zhang S, Guida WC, et al:
Selective chemical probe inhibitor of Stat3, identified through
structure-based virtual screening, induces antitumor activity. Proc
Natl Acad Sci USA. 104:7391–7396. 2007. View Article : Google Scholar
|
|
103
|
Lin L, Amin R, Gallicano GI, et al: The
STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers
with disrupted TGF-β signaling. Oncogene. 28:961–972.
2009.PubMed/NCBI
|
|
104
|
Hayakawa F, Sugimoto K, Kurahashi S, et
al: A novel direct STAT3 inhibitor OPB-31121 induces tumor-specific
growth inhibition in a wide4 range of hematopoietic malignacies and
effectively suppresses the chemotherapy resistant quiescent cell in
vivo. 52nd ASH Ann Meet & Expo III-56. 2010
|
|
105
|
Lo H-W, Cao X, Zhu H and Ali-Osman F:
Constitutively activated STAT3 frequently coexpresses with
epidermal growth factor receptor in high-grade gliomas and
targeting STAT3 sensitizes them to Iressa and akylators. Clin
Cancer Res. 14:6042–6054. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Real PJ, Sierra A, De Juan A, Segovia JC,
Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via
Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer
cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Oh D, Han S, Kim TM, et al: A phase I,
open-label, nonrandomized trial of OPB-31121, a STAT3 inhibitor, in
patients with advanced solid tumors. J Clin Oncol.
28:e130562010.
|
|
108
|
Sartor CI, Dziubinski ML, Yu C-L, Jove R
and Ethier SP: Role of epidermal growth factor receptor and STAT-3
activation in autonomous proliferation of SUM-102PT human breast
cancer cells. Cancer Res. 57:978–987. 1997.PubMed/NCBI
|
|
109
|
Garcia R, Yu C-L, Hudnall A, et al:
Constitutive activation of Stat3 in fibroblasts transformed by
diverse oncoproteins and in breast carcinoma cells. Cell Growth
Differ. 8:1267–1276. 1997.PubMed/NCBI
|
|
110
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Haura EB, Zheng Z, Song L, Cantor A and
Bepler G: Activated epidermal growth factor receptor-Stat-3
signaling promotes tumor survival in vivo in non-small cell lung
cancer. Clin Cancer Res. 11:8288–8294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Gao SP, Mark KG, Leslie K, et al:
Mutations in the EGFR kinase domain mediate STAT3 activation via
IL-6 production in human lung adenocarcinomas. J Clin Invest.
117:3846–3856. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Pfeiffer M, Hartmann T, Leick M, Catusse
J, Schmitt-Graeff A and Burger M: Alternative implication of CXCR4
in JAK2/STAT3 activation in small cell lung cancer. Br J Cancer.
100:1949–1956. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Quintanilla-Martinez L, Kremer M, Specht
K, et al: Analysis of signal transducer and activator of
transcription 3 (Stat3) pathway in multiple myeloma, Stat3
activation and cyclin D1 dysregulation are mutually exclusive
events. Am J Pathol. 162:1449–1461. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Chen C-L, Loy A, Cen L, et al: Signal
transducer and activator of transcription 3 is involved in cell
growth and survival of human rhabdomyosarcoma and osteosarcoma
cells. BMC Cancer. 7:1112007. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Grandis JR, Drenning SD, Chakraborty A, et
al: Requirement of Stat3 but not Stat1 activation for epidermal
growth factor receptor-mediated cell growth in vitro. J Clin
Invest. 102:1385–1392. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Grandis JR, Zeng Q and Drenning SD:
Epidermal growth factor receptor-mediated Stat3 singaling blocks
apoptosis in head and neck cancer. Laryngoscope. 110:868–874. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Sriuranpong V, Park JI, Amornphimoltham P,
Patel V, Nelkin BD and Gutkind JS: Epidermal growth factor
receptor-independent constitutive activation of STAT3 in head and
neck squamous cell carcimoma is mediated by the autocrine/paracrine
stimulation of the interleukin 6/gp130. Cancer Res. 63:2948–2956.
2003.
|
|
119
|
Ni Z, Lou W, Leman ES and Gao AC:
Inhibition of constitutively activated Stat3 signaling pathway
suppresses growth of prostate cancer cells. Cancer Res.
60:1225–1228. 2000.PubMed/NCBI
|
|
120
|
Barton BE, Murphy TF, Adem P, Watson RA,
Irwin RJ and Huang HF: IL-6 signaling by STAT3 participates in the
change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat
prostatic epithelial cells. BMC Cancer. 1:192001. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
DeMiguel F, Lee SO, Lou W, et al: Stat3
enhances the growth of LNCaP human prostate cancer cells in intact
and castrated male nude mice. Prostate. 52:123–129. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Barton BE, Karras JG, Murphy TF, Barton A
and Huang HF-S: Signal transducer and activator of transcription 3
(STAT3) activation in prostate cancer: direct STAT3 inhibition
induces apoptosis in prostate cancer lines. Mol Cancer Ther.
3:11–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Sanchez A, Nagy P and Thorgeirsson SS:
STAT-3 activity in chemically-induced hepatocellular carcinoma. Eur
J Cancer. 39:2093–2098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Dhir R, Ni Z, Lou W, De Miguel F, Grandis
JR and Gao AC: Stat3 activation in prostatic carcinomas. Prostate.
51:241–246. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sachez-Ceja SG, Reyes-Maldonado E,
Vazquez-Manriquez ME, Lopez-Luna JJ, Belmont A and
Gutierrez-Castellanos S: Differential expression of STAT5 and
Bcl-xL, and high expression of Neu and STAT3 in
non-small-cell lung carcinoma. Lung Cancer. 54:163–168.
2006.PubMed/NCBI
|
|
126
|
David D, Rajappan LM, Balachandran K,
Thulaseedharan JV, Nair AS and Pillai RM: Prognostic significance
of STAT3 and phosphorylated STAT3 in human soft tissue tumors - a
clinicopathological analysis. J Exp Clin Cancer Res. 30:562011.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Niu G, Wright KL, Huang M, et al:
Constitutive STAT3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Gritsko T, Williams A, Turkson J, et al:
Persistent activation of Stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Gao L, Li F, Dong B, et al: Inhibition of
STAT3 and ErbB2 suppresses tumor growth, enhances radiosensitivity,
and induces mitochondria-dependent apoptosis in glioma cells. Intl
J Radiat Oncol Biol Phys. 77:1223–1231. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Fuh B, Sobo M, Cen L, et al: LLL-3
inhibits STAT3 activity, suppresses glioblastoma cell growth and
prolongs survival in a mouse glioblastoma model. Br J Cancer.
100:106–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: a small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Zhang X, Yue P, Fletcher S, Zhao W,
Gunning PT and Turkson J: A novel small-molecule disrupts Stat3 SH2
domain-phosphotyrosine interactions and Stat3-dependent tumor
processes. Biochem Pharmacol. 79:1398–1409. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Fletcher S, Singh J, Zhang X, et al:
Disruption of transcriptionally active Stat3 dimers with
non-phosphorylated, salicylic acid-based small molecules: potent in
vitro and tumor cell activities. Chem Biol Chem. 10:1959–1964.
2009. View Article : Google Scholar
|
|
135
|
Siddiquee KAZ, Gunning PT, Glenn M, et al:
An oxazole-based small-molecule Stat3 inhibitor modulates Stat3
stability and processing and incuces antitumor cell effects. ACS
Chem Biol. 2:787–798. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Uehara Y, Mochizuki M, Matsuno K, Haino T
and Asai A: Novel high-throughput screening system for identifying
STAT3-SH2 antagonists. Biochem Biophys Res Commun. 380:627–631.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Ball S, Li C, Li P-K and Lin J: The small
molecule, LLL12, inhibits STAT3 phosphorylation and induces
apoptosis in medulloblastoma and glioblastoma cells. PLoS One.
6:e188202011. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Lin L, Hutzen B, Li P-K, et al: A novel
small molecule, LLL12, inhibits STAT3 phosphorylation and activites
and exhibits potent growth-suppressive activity in human cancer
cells. Neoplasia. 12:39–50. 2010.PubMed/NCBI
|
|
139
|
Matsuno K, Masuda Y, Uehara Y, et al:
Identification of a new series of STAT3 inhibitors by virtual
screening. ACS Med Chem Lett. 1:371–375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ashizawa T, Miyata H, Ishii H, et al:
Antitumor activity of a novel small molecule STAT3 inhibitor
against a human lymphoma cell line with high STAT3 activation. Int
J Oncol. 38:1245–1252. 2011.PubMed/NCBI
|
